Is combination antifungal therapy for invasive aspergillosis a necessity in hematopoietic stem-cell transplant recipients?

Current Opinion in Infectious Diseases

Volumn 19, Issue 4, 2006, Pages 371-379

  Leather, Helen L ^a   Wingard, John R ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Combination antifungal therapy; Hematopoietic stem cell transplantation; Invasive aspergillosis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ALGORITHM; ASPERGILLOSIS; ASPERGILLUS; BRONCHOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; FUNGUS CULTURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC SYSTEM TUMOR; HIGH RISK PATIENT; HUMAN; LUNG LAVAGE; MORTALITY; MYCOSIS; NONHUMAN; PATIENT MONITORING; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; DRUG THERAPY, COMBINATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MICE; RANDOMIZED CONTROLLED TRIALS;

EID: 33745625648     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qco.0000235165.08797.81     Document Type: Review

References (35)

1. Johnson MD, MacDougall C, Ostrosky-Zeichner L, et al. Combination antifungal therapy. Antimicrob Agents Chemother 2004; 48:693-715.
2. Mukherjee PK, Sheejan DJ, Hitchcock CA, Ghannoum MA. Combination treatment of invasive fungal infections. Clin Microbiol Rev 2005; 18:163-194. An excellent, up-to-date review of in-vitro and in-vivo antifungal combination data. Limitations of in-vitro data and difficulties in extrapolating the results to humans are described.
3. Petraitis V, Patraitiene R, Sarafandi AA, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003; 187:1834-1843.
4. Kirkpatrick WR, Coco BJ, Patterson TF. Sequential or combination antifungal therapy with voriconazole and liposomal amphotericin B in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2006; 50:1567-1569.
5. Dennis CG, Greco WR, Brun Y, et al. Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47/phox-/- mouse model of chronic granulomatous disease. Antimicrob Agents Chemother 2006; 50:422-427.
6. Clemons KV, Espiritu M, Parmar R, Stevens DA. Comparative efficacies of conventional amphotericin B, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob Agents Chemother 2005; 49:4867-4875.
7. MacCallum DM, Whyte JA, Odds FC. Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. Antimicrob Agents Chemother 2005; 49:3697-3701.
8. Imai J, Singh G, Fernandez B, et al. Efficacy of Abelcet and caspofungin, alone or in combination, against CNS aspergillosis in a murine model. J Antimicrob Chemother 2005; 56:166-171.
9. Chandrasekar PH, Cutright JL, Manavathu EK. Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis. Clin Microbiol Infect 2004; 10:925-928.
10. Perfect JR, Cox GM, Lee JY, et al. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis 2001; 33:1824-1833.
11. Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34:909-917.
12. ••] in HSCT recipients. Randomized studies are needed to conclusively answer the question.
13. Aliff TA, Maslak PG, Jurcic JG, et al. Refractory aspergillus pneumonia in patients with acute leukaemia. Successful therapy with combination caspofungin and liposomal amphotericin B. Cancer 2003; 97:1025-1032.
14. Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39:797-802.
15. Marr KA, Boeckh M, Kim HW. Reply to Cesaro and Visintin. Clin Infect Dis 2005; 40:1075-1076. Follow-up 1-year overall survival data with the combination of voriconazole and caspofungin were no different to monotherapy; however, there were fewer deaths from IFI among the combination recipients. Trials with fungal-infection-free survival need to be developed to address any advantage in survival.
16. Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003; 98:292-299.
17. Kontoyiannis DP, Boktour M, Hanna H, et al. Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis. Cancer 2005; 103:2334-2337.
18. Maertens J, Glashmacher A, Herbrecht R, et al. Multicenter, noncomparative study of caspofungin (CAS) combined with other antifungals in adults with invasive aspergillosis (IA) refractory (R) or intolerant (I) to prior therapy (Rx): final data. In: Program and Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington DC; 16-19 December 2005; Washington DC: American Society for Microbiology, 2005. Abstract M-954.
19. Ratanatharathorn V, Flynn P, van Burik JA, et al. Micafungin in combination with systemic antifungal agents in the treatment of refractory aspergillosis (RA) in bone marrow transplant (BMT) patients. Blood 2002; 100:627a.
20. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-415.
21. Viscoli C. Combination therapy for invasive aspergillosis. Clin Infect Dis 2004; 39:803-805.
22. Ioannidis JP, Haidich AB, Pappa M, et al. Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA 2001; 286:821-830.
23. Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computer tomography scans in patients with neutropenia. J Clin Oncol 2001; 19:253-259.
24. Bennett JE. Salvage therapy for aspergillosis. Clin Infect Dis 2005; 41 (suppl 6):S387-S388. Good overview of issues attached to salvage antifungal trials. The article highlights areas for consensus and incorporation into future clinical trials to enable comparisons between trials.
25. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326:845-851.
26. Penack O, Reinwald M, Schmidt-Hieber M, et al. Low dose liposomal amphotericin B (L-AmB) as prophylaxis of invasive fungal infections (IFI) in patients (pts) with prolonged neutropenia (N): Results from a phase-III trial. In: Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington DC; 16-19 December 2005; Washington DC: American Society for Microbiology, 2005. Abstract M-975.
27. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole or prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103:1527-1533.
28. Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003; 138:705-713.
29. Mattiuzzi GN, Alvarado G, Giles FJ, et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother 2006; 50:143-147. Interestingly, there was no difference between itraconazole and caspofungin as prophylaxis in hematological malignancy patients. The article provides evidence that there may be a role for echinocandin therapy in the prophylactic setting.
30. Mattiuzzi GN, Estey E, Raad I, et al. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. Cancer 2003; 97:450-456.
31. th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington DC; 16-19 December 2005; Washington DC: American Society for Microbiology, 2005. Abstract M-716.
32. Cornely O, Maertens J, Winston D, et al. Posaconazole vs standard azole (FLU/ITRA) therapy for prophylaxis of invasive fungal infections (IFIs) among high risk neutropenic patients: results of a randomized, multicenter trial. Blood 2005; 106. Abstract 1844.
33. van Burik JH, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39:1407-1416.
34. Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41:1242-1250. An excellent study demonstrating that surrogate markers (galactomannan antigen and radiological testing) can guide therapy as effectively as empirical therapy. This presumptive or preemptive approach is advantageous in that it spares a proportion of the population from therapy without reducing efficacy and allows therapy to start earlier in some patients.
35. Greene R. The radiological spectrum of pulmonary aspergillosis. Med Mycol 2005; 43 (suppl 1):S147-S154.